Literature DB >> 11673821

Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome.

S Kenwrick1, H Woffendin, T Jakins, S G Shuttleworth, E Mayer, L Greenhalgh, J Whittaker, S Rugolotto, T Bardaro, T Esposito, M D'Urso, F Soli, A Turco, A Smahi, D Hamel-Teillac, S Lyonnet, J P Bonnefont, A Munnich, S Aradhya, C D Kashork, L G Shaffer, D L Nelson, M Levy, R A Lewis.   

Abstract

Incontinentia pigmenti (IP), or "Bloch-Sulzberger syndrome," is an X-linked dominant disorder characterized by abnormalities of skin, teeth, hair, and eyes; skewed X-inactivation; and recurrent miscarriages of male fetuses. IP results from mutations in the gene for NF-kappaB essential modulator (NEMO), with deletion of exons 4-10 of NEMO accounting for >80% of new mutations. Male fetuses inheriting this mutation and other "null" mutations of NEMO usually die in utero. Less deleterious mutations can result in survival of males subjects, but with ectodermal dysplasia and immunodeficiency. Male patients with skin, dental, and ocular abnormalities typical of those seen in female patients with IP (without immunodeficiency) are rare. We investigated four male patients with clinical hallmarks of IP. All four were found to carry the deletion normally associated with male lethality in utero. Survival in one patient is explained by a 47,XXY karyotype and skewed X inactivation. Three other patients possess a normal 46,XY karyotype. We demonstrate that these patients have both wild-type and deleted copies of the NEMO gene and are therefore mosaic for the common mutation. Therefore, the repeat-mediated rearrangement leading to the common deletion does not require meiotic division. Hypomorphic alleles, a 47,XXY karyotype, and somatic mosaicism therefore represent three mechanisms for survival of males carrying a NEMO mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673821      PMCID: PMC1235532          DOI: 10.1086/324591

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  26 in total

1.  De novo factor VIII gene intron 22 inversion in a female carrier presents as a somatic mosaicism.

Authors:  J Oldenburg; S Rost; O El-Maarri; M Leuer; K Olek; C R Müller; R Schwaab
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males.

Authors:  J Clayton-Smith; P Watson; S Ramsden; G C Black
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

3.  X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling.

Authors:  R Döffinger; A Smahi; C Bessia; F Geissmann; J Feinberg; A Durandy; C Bodemer; S Kenwrick; S Dupuis-Girod; S Blanche; P Wood; S H Rabia; D J Headon; P A Overbeek; F Le Deist; S M Holland; K Belani; D S Kumararatne; A Fischer; R Shapiro; M E Conley; E Reimund; H Kalhoff; M Abinun; A Munnich; A Israël; G Courtois; J L Casanova
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

4.  Incontinentia pigmenti in a surviving male is accompanied by hypohidrotic ectodermal dysplasia and recurrent infection.

Authors:  S Mansour; H Woffendin; S Mitton; I Jeffery; T Jakins; S Kenwrick; V A Murday
Journal:  Am J Med Genet       Date:  2001-03-01

5.  Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia.

Authors:  A Jain; C A Ma; S Liu; M Brown; J Cohen; W Strober
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

6.  A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).

Authors:  J Zonana; M E Elder; L C Schneider; S J Orlow; C Moss; M Golabi; S K Shapira; P A Farndon; D W Wara; S A Emmal; B M Ferguson
Journal:  Am J Hum Genet       Date:  2000-10-24       Impact factor: 11.025

7.  The Conradi-Hünermann-Happle syndrome (CDPX2) and emopamil binding protein: novel mutations, and somatic and gonadal mosaicism.

Authors:  C Has; L Bruckner-Tuderman; D Müller; M Floeth; E Folkers; D Donnai; H Traupe
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

8.  Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma).

Authors:  S Aradhya; G Courtois; A Rajkovic; R A Lewis; M Levy; A Israël; D L Nelson
Journal:  Am J Hum Genet       Date:  2001-02-08       Impact factor: 11.025

9.  Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice.

Authors:  D Rudolph; W C Yeh; A Wakeham; B Rudolph; D Nallainathan; J Potter; A J Elia; T W Mak
Journal:  Genes Dev       Date:  2000-04-01       Impact factor: 11.361

10.  Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium.

Authors:  A Smahi; G Courtois; P Vabres; S Yamaoka; S Heuertz; A Munnich; A Israël; N S Heiss; S M Klauck; P Kioschis; S Wiemann; A Poustka; T Esposito; T Bardaro; F Gianfrancesco; A Ciccodicola; M D'Urso; H Woffendin; T Jakins; D Donnai; H Stewart; S J Kenwrick; S Aradhya; T Yamagata; M Levy; R A Lewis; D L Nelson
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

View more
  22 in total

1.  The Incontinentia Pigmenti Genetic Biobank: study design and cohort profile to facilitate research into a rare disease worldwide.

Authors:  Francesca Fusco; Valeria Valente; Dario Fergola; Alessandra Pescatore; Maria Brigida Lioi; Matilde Valeria Ursini
Journal:  Eur J Hum Genet       Date:  2019-06-23       Impact factor: 4.246

2.  Clinical utility gene card: for incontinentia pigmenti.

Authors:  Francesca Fusco; Alessandra Pescatore; Julie Steffann; Jean-Paul Bonnefont; Judite De Oliveira; Maria Brigida Lioi; Matilde Valeria Ursini
Journal:  Eur J Hum Genet       Date:  2019-07-09       Impact factor: 4.246

Review 3.  Genodermatoses caused by genetic mosaicism.

Authors:  M Vreeburg; M A M van Steensel
Journal:  Eur J Pediatr       Date:  2012-11-01       Impact factor: 3.183

Review 4.  Mosaicism in Cutaneous Disorders.

Authors:  Young H Lim; Zoe Moscato; Keith A Choate
Journal:  Annu Rev Genet       Date:  2017-11-27       Impact factor: 16.830

5.  Incontinentia pigmenti: a rare genodermatosis in a male child.

Authors:  Dinesh Kumar Narayana Swamy; Arulkumaran Arunagirinathan; Revathi Krishnakumar; Sivaraman Sangili
Journal:  J Clin Diagn Res       Date:  2015-02-01

6.  Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.

Authors:  Lisa T Emrick; Lauren Murphy; Alireza A Shamshirsaz; Rodrigo Ruano; Christopher I Cassady; Liu Liu; Fengqi Chang; V Reid Sutton; Marilyn Li; Ignatia B Van den Veyver
Journal:  Am J Med Genet A       Date:  2014-07-14       Impact factor: 2.802

7.  Absence of an osteopetrosis phenotype in IKBKG (NEMO) mutation-positive women: A case-control study.

Authors:  Morten Frost; Michaela Tencerova; Christina M Andreasen; Thomas L Andersen; Charlotte Ejersted; Dea Svaneby; Weimin Qui; Moustapha Kassem; Allahdad Zarei; William H McAlister; Deborah J Veis; Michael P Whyte; Anja L Frederiksen
Journal:  Bone       Date:  2019-01-16       Impact factor: 4.398

8.  Incontinentia pigmenti: clinical observation of 40 Korean cases.

Authors:  Beom Joon Kim; Hyo Seung Shin; Chong Hyun Won; Jong Hee Lee; Kyu Han Kim; Myeung Nam Kim; Byung In Ro; Oh Sang Kwon
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

9.  Incontinentia pigmenti presenting as hypodontia in a 3-year-old girl: a case report.

Authors:  Dárcio Kitakawa; Patrícia Campos Fontes; Fernando Augusto Cintra Magalhães; Janete Dias Almeida; Luiz Antonio Guimarães Cabral
Journal:  J Med Case Rep       Date:  2009-11-10

Review 10.  Lessons learnt from large-scale exon re-sequencing of the X chromosome.

Authors:  F Lucy Raymond; Annabel Whibley; Michael R Stratton; Jozef Gecz
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.